What unique aspects, with respect to all-cause mortality outcomes and baseline LDL-C levels, were observed in the ODYSSEY Outcomes Trial and how would you translate these results into patient care?

What unique aspects, with respect to all-cause mortality outcomes and baseline LDL-C levels, were observed in the ODYSSEY Outcomes Trial and how would you translate these results into patient care?

What unique aspects, with respect to all-cause mortality outcomes and baseline LDL-C levels, were observed in the ODYSSEY Outcomes Trial and how would you translate these results into patient care?


Created by

 CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Phillipe Steg, MD

Phillipe Steg, MD

Professor of Cardiology Université Paris – Diderot, Sorbonne-Paris Cité Professor, National Heart and Lung Institute Imperial College, London, UK Director, Coronary Care Unit Hôpital Bichat Paris, France